Oral, intestinally absorbed food ingredient for endurance enhancement
ASD-NP6 is a patented food ingredient combining alpha-cyclodextrin and capric acid to boost physical and mental endurance. It is water-soluble, tasteless, and slows sugar absorption. Suitable for various foods, it is ready for commercial production and partnerships.
Overview
ASD-NP6 is an innovative food ingredient designed to enhance physical and mental endurance. It is an inclusion complex of alpha-cyclodextrin (a soluble fiber) and capric acid, both naturally occurring substances with established safety profiles. This patented formulation is water-soluble, colorless, and tasteless, making it an ideal additive for a wide range of food products. By slowing sugar absorption and improving cognitive function, ASD-NP6 provides a dual benefit for consumers seeking sustained energy and endurance.
Technical specifications
- Composition: ASD-NP6 combines alpha-cyclodextrin and capric acid in a clathrate structure, which enhances intestinal absorption and synergistically boosts the benefits of each component.
- Functionality: The slow digestibility of ASD-NP6 helps minimize glucose fluctuations, while its emulsifying properties facilitate the transition of capric acid through the intestinal mucosa.
- Applications: ASD-NP6 can be incorporated into solid foods like bread, nutritional bars, and cereals, as well as beverages and snacks. It is particularly suitable for products aimed at enhancing endurance and reducing fatigue.
Technology readiness level
ASD-NP6 is at Technology Readiness Level 8, indicating it is in the final stages of validation and ready for commercial deployment. The production phase has commenced, and the technology is open for licensing, co-development, and fee-for-service partnerships to expand its application across various food products.
About ASDERA
ASDERA is a biotechnology company that develops targeted medical interventions by utilizing a patented computational biostatistics platform. This approach identifies complex genetic risk factors that were often considered inconclusive in other studies, particularly within small-scale epidemiological data or previously failed phase 2/3 clinical trials. By analyzing genetic structures and neighborhood hotspots, the company aims to uncover missing heritability and translate these findings into therapeutic candidates for conditions with significant unmet medical needs. ASDERA operates as a virtual organization that outlicenses its patented assets once development milestones are achieved.
The company focuses on therapeutic areas including aging-related health, oncology, and orphan diseases. Its pipeline includes candidates for developmental language disorders in children at risk of autism, lysosomal storage diseases, and metabolic syndrome, as well as nutritional formulations designed as fasting mimetics to improve aging-related processes. ASDERA serves the broader pharmaceutical and healthcare sector by providing a novel method for drug discovery and asset development. Its research has historically addressed various health challenges, including neurodegeneration, cardiovascular health, and infectious disease responses.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.